1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH): Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process: Q5E. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guide line.pdf. Accessed 21 Jan 2021.
2. European Medicines Agency. Guideline on Similar Biological Medicinal Products, CHMP/437/04 Rev 1. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf. Accessed 21 Jan 2021.
3. US Food and Drug Administration. Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009: Guidance for Industry. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM444661.pdf. Accessed 21 Jan 2021.
4. Declerck P, Mourad FR, Rudd PM. Biosimilarity versus manufacturing change: two distinct concepts. Pharm Res. 2016;33:261–8. https://doi.org/10.1007/s11095-015-1790-3. Accessed 7 February 2021.
5. Jefferis R. Biologics: structural heterogeneity and immunogenicity. Br Jo Hosp Medi. 2017. https://doi.org/10.12968/hmed.2017.78.8.443. Accessed 7 February 2021.